[Rapid outpatient diagnostic pathways for lung cancer: Evaluation after one year].

Parcours de diagnostic rapide du cancer du poumon : évaluation à un an.
Ambulatoire Cancer du poumon Centre diagnostic rapide Coordination nurses Délais de prise en charge IDE de coordination Lung Cancer Care Coordination program Outpatient Timeliness of Care

Journal

Revue des maladies respiratoires
ISSN: 1776-2588
Titre abrégé: Rev Mal Respir
Pays: France
ID NLM: 8408032

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 03 12 2020
accepted: 28 07 2021
pubmed: 11 11 2021
medline: 18 11 2021
entrez: 10 11 2021
Statut: ppublish

Résumé

The introduction of coordinated care pathways for lung cancer diagnosis and treatment is a complex process. The purpose of the French Cancer Plan 2014-2019 was to improve referral to treatment waiting times in people with suspected malignancy. The aim of this study was to assess a rapid outpatient diagnostic program for lung cancer established in 2016. This retrospective study was carried out in the Pulmonology Department at Tenon Hospital, Paris, France between May 2016 and May 2017. During this period, 118 patients (60%) of patients in the pathway were diagnosed with lung cancer. The median waiting time to first consultation (D1) was 4 (2-7) days. The median waiting time between diagnosis and treatment decision (D4) was 4 (0-8) days. The median waiting time to the first treatment (D5) was 10 (4-15) days for chemotherapy and 27 (16-34) days for surgery. The median waiting time between the first abnormal chest X-ray and the first treatment (D6) was 49 days (34-70). Referral to treatment waiting times was consistent with international recommendations. Coordinating nurses improved care pathways in lung cancer patients.

Identifiants

pubmed: 34756758
pii: S0761-8425(21)00366-1
doi: 10.1016/j.rmr.2021.07.005
pii:
doi:

Types de publication

Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

904-913

Informations de copyright

Copyright © 2021 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

F Millet (F)

Service de pneumologie et oncologie thoracique, AP-HP, hôpital Tenon et GRC 04 Theranoscan Sorbonne université, Paris, France.

M Wislez (M)

Service de pneumologie et oncologie thoracique, AP-HP, hôpital Tenon et GRC 04 Theranoscan Sorbonne université, Paris, France; Service de pneumologie, AP-HP, hôpital Cochin, Paris, France.

V Fallet (V)

Service de pneumologie et oncologie thoracique, AP-HP, hôpital Tenon et GRC 04 Theranoscan Sorbonne université, Paris, France.

M Antoine (M)

Service d'anatomopathologie, AP-HP, hôpital Tenon et GRC 04 Theranoscan Sorbonne Université, Paris, France.

J Assouad (J)

Service de chirurgie thoracique et vasculaire, AP-HP Hôpital Tenon, Paris, France.

M Baud (M)

Service de pneumologie et oncologie thoracique, AP-HP, hôpital Tenon et GRC 04 Theranoscan Sorbonne université, Paris, France.

A Canellas (A)

Service de pneumologie et oncologie thoracique, AP-HP, hôpital Tenon et GRC 04 Theranoscan Sorbonne université, Paris, France.

A-M Ruppert (AM)

Service de pneumologie et oncologie thoracique, AP-HP, hôpital Tenon et GRC 04 Theranoscan Sorbonne université, Paris, France.

S Guegan (S)

Service de pneumologie et oncologie thoracique, AP-HP, hôpital Tenon et GRC 04 Theranoscan Sorbonne université, Paris, France.

L Rosencher (L)

Service de pneumologie et oncologie thoracique, AP-HP, hôpital Tenon et GRC 04 Theranoscan Sorbonne université, Paris, France.

C Epaud (C)

Service de pneumologie et oncologie thoracique, AP-HP, hôpital Tenon et GRC 04 Theranoscan Sorbonne université, Paris, France.

D Moal (D)

Service de pneumologie et oncologie thoracique, AP-HP, hôpital Tenon et GRC 04 Theranoscan Sorbonne université, Paris, France.

J Cadranel (J)

Service de pneumologie et oncologie thoracique, AP-HP, hôpital Tenon et GRC 04 Theranoscan Sorbonne université, Paris, France.

A Lavolé (A)

Service de pneumologie et oncologie thoracique, AP-HP, hôpital Tenon et GRC 04 Theranoscan Sorbonne université, Paris, France. Electronic address: armelle.lavole@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH